“…These compounds were designed based on the reported biological activities of isatin itself (I), semaxanib (SU5416) II, and sunitinib III, (previously known as SU11248), Beside FDA approved anti-cancer drug for the treatment of renal cell carcinoma and gastric cancer, the Sunitinib is also in phase I/II clinical trial for the treatment of acute myeloid leukemia 32) via inhibiting the FLT3 gene [33][34][35] . Finally, other derivatives IV 15,36) [ 13,24], which have been reported with strong anticancer activity ( Figure 10 The zebrafish embryos did not develop blood vessels when treated with 1 µM SU-5416, but positive o-dianisidine staining indicated that this tyrosine kinase inhibitor did not affect the blood cells formation in zebrafish embryos. In contrast, compounds 3c and 3f specifically inhibited blood cell formation, but did not affect the blood vessel formation in zebrafish embryos, whereas the other compounds did not affect the zebrafish embryos.…”